;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • 2M BioTech, Calico deal

    2M BioTech L.P., Dallas, Texas Calico LLC, South San Francisco, Calif. Business: Neurology 2M BioTech granted Calico exclusive, worldwide rights to develop and commercialize a portfolio of modulators of nicotinamide …

    Published on 9/15/2014
  • Abzena, UCL deal

    Abzena Ltd. (LSE:ABZA), Babraham, U.K. University College London (UCL), London, U.K. Business: Ophthalmic, Antibodies Abzena's Antitope Ltd. subsidiary and University College London partnered to humanize an anti-leucine…

    Published on 9/15/2014
  • Allegro Diagnostics, Veracyte deal

    Allegro Diagnostics Inc., Maynard, Mass. Veracyte Inc. (NASDAQ:VCYT), South San Francisco, Calif. Business: Diagnostic Veracyte will acquire diagnostic company Allegro for $7.8 million in cash and $13.2 million in …

    Published on 9/15/2014
  • Alpine Biosciences, Oncothyreon deal

    Alpine Biosciences Inc., Seattle, Wash. Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Business: Drug delivery Oncothyreon acquired drug delivery company Alpine for 9.2 million Oncothyreon shares, or about $27.1 million…

    Published on 9/15/2014
  • Banyan Biomarkers, Abbott deal

    Banyan Biomarkers Inc., Alachua, Fla. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Inflammation Banyan granted Abbott undisclosed rights to IP related to traumatic brain injury (TBI) biomarkers for …

    Published on 9/15/2014
  • Calbiotech, Intrinsic LifeSciences deal

    Calbiotech Inc., Spring Valley, Calif. Intrinsic LifeSciences LLC, La Jolla, Calif. Business: Diagnostic Calbiotech partnered with Intrinsic LifeSciences to develop and validate ELISA test kits for hepcidin, a hormone …

    Published on 9/15/2014
  • CFR Pharmaceuticals, Abbott deal

    CFR Pharmaceuticals S.A., Santiago, Chile Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Generics Abbott began a tender offer to acquire generics specialty company CFR for $2.9 billion in cash (see …

    Published on 9/15/2014
  • Corgenix Medical Corp., Orgentec Diagnostika deal

    Corgenix Medical Corp. (OTCBB:CONX), Broomfield, Colo. Orgentec Diagnostika GmbH, Mainz, Germany Business: Diagnostic Orgentec will acquire fellow diagnostic company Corgenix for about $16 million in cash. Corgenix …

    Published on 9/15/2014
  • Eisai, Concordia deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Concordia Pharmaceuticals Inc., Fort Lauderdale, Fla. Business: Neurology Eisai will sell to Concordia U.S. and Puerto Rican commercialization rights to anticonvulsant Zonegran …

    Published on 9/15/2014
  • Genomic Health, New England Biolabs deal

    Genomic Health Inc. (NASDAQ:GHDX), Redwood City, Calif. New England Biolabs Inc., Ipswich, Mass. Business: Supply/Service New England Biolabs received an exclusive license to use Genomic Health's ribosomal RNA (rRNA) …

    Published on 9/15/2014
  • iBio, Kanematsu deal

    iBio Inc. (NYSE-M:IBIO), Newark, Del. Kanematsu Corp. (Tokyo:8020), Tokyo, Japan Business: Biomanufacturing iBio granted Kanematsu's Kanematsu Chemicals Corp. subsidiary rights to market iBio's iBioLaunch platform in …

    Published on 9/15/2014
  • J&J, University of Toronto deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. University of Toronto, Toronto, Ontario Business: Neurology Johnson & Johnson's Janssen Biotech Inc. subsidiary and J&J's Innovation Center in California partnered with …

    Published on 9/15/2014
  • Kaketsuken, Daiichi Sankyo deal

    Kaketsuken, Kumamoto, Japan Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Infectious The Chemo-Sero Therapeutic Research Institute (Kaketsuken) granted Daiichi Sankyo non-exclusive rights to co-…

    Published on 9/15/2014
  • Ligand, Avion deal

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Avion Pharmaceuticals LLC, Atlanta, Ga. Business: Drug delivery, Pharmaceuticals Ligand granted Avion undisclosed development and commercialization rights to …

    Published on 9/15/2014
  • Merck KGaA, Massachusetts General Hospital deal

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Massachusetts General Hospital, Boston, Mass. Business: Autoimmune Merck's EMD Serono Research and Development Institute Inc. subsidiary and Massachusetts General Hospital …

    Published on 9/15/2014
  • NeuroVive, OnCore Biopharma deal

    NeuroVive Pharmaceutical AB (SSE:NVP), Lund, Sweden OnCore Biopharma Inc., Doylestown, Pa. Business: Infectious OnCore Biopharma received exclusive, worldwide rights to develop and commercialize NeuroVive's preclinical …

    Published on 9/15/2014
  • Northwestern University, Panther Biotechnology deal

    Northwestern University, Evanston, Ill. Panther Biotechnology Inc. (OTCQB:PBYA), Evanston, Ill. Business: Cancer Panther received an option from the university to license exclusive, worldwide rights to numonafide. The …

    Published on 9/15/2014
  • Olympus Biotech, Novo Nordisk deal

    Olympus Biotech Corp., Hopkinton, Mass. Novo Nordisk A/S (CSE:NVO;NYSE:NVO), Bagsvaerd, Denmark Business: Biomanufacturing Olympus sold to Novo Nordisk Olympus' manufacturing facility in West Lebanon, N.H., which has …

    Published on 9/15/2014
  • Paradigm, Tesaro deal

    Paradigm Inc., Ann Arbor, Mich. Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Cancer Paradigm partnered with Tesaro to characterize patient tissue samples from clinical trials to predict which patients may be …

    Published on 9/15/2014
  • Pfizer, Astellas deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cardiovascular The pharmas agreed to terminate on March 31, 2015, a 2009 deal to co-commercialize Caduet amlodipine …

    Published on 9/15/2014
  • Redx Pharma, AstraZeneca deal

    Redx Pharma Ltd., Liverpool, U.K. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer AstraZeneca partnered with Redx Pharma to discover and develop molecules targeting an undisclosed "genetic driver" of …

    Published on 9/15/2014
  • Roche, Garvan Institute of Medical Research deal

    Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Garvan Institute of Medical Research, Sydney, Australia Business: Other Roche and the Garvan Institute partnered to develop new methods to analyze regions of the epigenome…

    Published on 9/15/2014
  • Shin Nippon Biomedical Laboratories, G2B deal

    Shin Nippon Biomedical Laboratories Ltd. (Tokyo:2395), Tokyo, Japan G2B Pharma Inc., Corte Madera, Calif. Business: Drug delivery Shin Nippon granted G2B an option for non-exclusive rights to its uco System nasal …

    Published on 9/15/2014
  • University of Pennsylvania, Novartis deal

    University of Pennsylvania, Philadelphia, Pa. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer The university and the pharma plan to build the Center for Advanced Cellular Therapeutics (CACT) to …

    Published on 9/15/2014
  • Ablynx, Boehringer Ingelheim deal

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Neurology Ablynx disclosed in its 1H14 earnings that Boehringer Ingelheim terminated a 2007 deal granting Boehringer …

    Published on 9/8/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993